Abiopharma

EVOGENE LTD (EVGN)

Symbol	EVGN
Name	EVOGENE LTD
Sector	INDUSTRIALS
Region	Middle East
Industry	BIOMED
Address	13 GAD FEINSTEIN STREET,PARK REHOVOT, P.O. BOX 4173, REHOVOT, 7414002, Israel
Telephone	08-9311900
Fax	08-9466724
Email	ofer.haviv@evogene.com
Website	www.evogene.com
Incorporation	Israel
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	TASE;NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001574565
Description	Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment. Additional info from NASDAQ: Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment.

2026-08-07 17:06

New Form SCHEDULE 13D/A - Evogene Ltd. Filed: 2026-08-07 AccNo: 0001213900-26-086674 Size: 25 KB

2026-08-06 06:56

FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-RECANATI LEON

2026-07-31 20:00

Immediate Report of Meeting

2026-07-30 11:00

Second Quarter 2026 Financial Results Release

2026-07-29 11:00

SCHEDULE 13D-L.I.A. Pure Capital. Ltd, Kfir Silberman, Invest Pro Shukai Hon Ltd, Ron Yair Pelrd

2026-07-27 08:23

New Form SCHEDULE 13D/A - Evogene Ltd. Filed: 2026-07-27 AccNo: 0001213900-26-081575 Size: 31 KB

2026-07-22 12:00

Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

2026-07-21 11:00

13D-L.I.A. Pure Capital. Ltd, Kfir Silberman, Invest Pro Shukai Hon Ltd, Ron Yair Pelrd

2026-07-20 16:47

New Form SCHEDULE 13D/A - Evogene Ltd. Filed: 2026-07-20 AccNo: 0001213900-26-079584 Size: 23 KB

2026-07-17 20:05

Other Report or Announcement